Viking Therapeutics (VKTX) Competitors $25.40 -0.64 (-2.46%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$25.56 +0.16 (+0.63%) As of 09/19/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, QGEN, BBIO, ROIV, MRNA, ELAN, VRNA, RVMD, and GRFSShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Grifols (GRFS). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company QIAGEN BridgeBio Pharma Roivant Sciences Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation. Do institutionals & insiders believe in VKTX or MDGL? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate VKTX or MDGL? Viking Therapeutics presently has a consensus target price of $87.50, indicating a potential upside of 244.49%. Madrigal Pharmaceuticals has a consensus target price of $483.38, indicating a potential upside of 9.88%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more volatility & risk, VKTX or MDGL? Viking Therapeutics has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, suggesting that its share price is 202% less volatile than the S&P 500. Does the media prefer VKTX or MDGL? In the previous week, Viking Therapeutics had 4 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for Viking Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.98 beat Madrigal Pharmaceuticals' score of 0.71 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, VKTX or MDGL? Viking Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.53-16.60Madrigal Pharmaceuticals$180.13M54.22-$465.89M-$12.85-34.24 Is VKTX or MDGL more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -19.98% -19.38% Madrigal Pharmaceuticals -54.68%-38.38%-27.32% SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$3.13B$5.81B$10.45BDividend YieldN/A2.36%5.61%4.56%P/E Ratio-16.6020.9180.5026.82Price / SalesN/A254.58452.1890.30Price / CashN/A46.4637.6661.43Price / Book3.229.6015.756.39Net Income-$109.96M-$53.22M$3.30B$271.80M7 Day Performance2.38%3.11%5.35%3.51%1 Month Performance-1.01%6.23%7.28%9.58%1 Year Performance-63.96%11.02%80.79%28.53% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.2567 of 5 stars$25.40-2.5%$87.50+244.5%-64.0%$2.86BN/A-16.6020MDGLMadrigal Pharmaceuticals3.9496 of 5 stars$425.60-1.5%$483.38+13.6%+88.4%$9.45B$180.13M-33.1290LLYEli Lilly and Company4.9971 of 5 stars$748.26-0.9%$941.35+25.8%-18.2%$708.20B$53.26B48.9147,000Trending NewsAnalyst ForecastQGENQIAGEN4.4431 of 5 stars$45.39+0.2%$49.69+9.5%+5.3%$10.09B$1.98B26.825,765Positive NewsBBIOBridgeBio Pharma4.3341 of 5 stars$51.47+0.5%$63.94+24.2%+95.8%$9.84B$221.90M-12.58400ROIVRoivant Sciences3.4508 of 5 stars$13.95-0.9%$17.67+26.6%+25.6%$9.53B$29.05M-19.93860Trending NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.5281 of 5 stars$23.88+1.6%$41.81+75.1%-61.6%$9.29B$3.24B-3.175,800ELANElanco Animal Health2.8079 of 5 stars$18.63+0.5%$17.33-6.9%+36.3%$9.25B$4.44B21.669,000VRNAVerona Pharma PLC American Depositary Share2.2321 of 5 stars$106.37-0.1%$109.00+2.5%+253.5%$9.17B$42.28M-107.4430Positive NewsRVMDRevolution Medicines4.2058 of 5 stars$46.20-0.8%$73.67+59.5%-4.1%$8.64B$11.58M-10.27250Trending NewsInsider TradeGRFSGrifols3.8387 of 5 stars$9.63-2.5%$10.30+7.0%+8.8%$6.62B$7.45B8.2323,822 Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors QIAGEN Competitors BridgeBio Pharma Competitors Roivant Sciences Competitors Moderna Competitors Elanco Animal Health Competitors Verona Pharma PLC American Depositary Share Competitors Revolution Medicines Competitors Grifols Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VKTX Stock Alerts